Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- REGULATORY NEWS IN BRIEF
December 22, 2008
- Non-Recommendation of HPV Screening Meets Strong Objections
December 22, 2008
- Astellas to Identify Its 3rd and 4th Franchise Fields
December 22, 2008
- Daiichi Sankyo Starts PIII Trial of DU-176b
December 22, 2008
- Urination Management Services Should Be Reimbursed: Dr Kuroda
December 22, 2008
- GSK Enhances Its Presence in CNS Field with Lamictal
December 22, 2008
- Takeda, CanBas Start PII Trial for CBP501 for Malignant Pleural Mesothelioma in US
December 22, 2008
- Galderma Aims at No. 1 Position in Dermatology
December 22, 2008
- Teijin Expects Approval of TMX-67 in US
December 22, 2008
- 33 Multinational Clinical Trials Reported in First 6 Months of FY2008
December 22, 2008
- BioWa Extends POTELLIGENT Technology License Agreement with GSK
December 22, 2008
- Okayama Univ. to Test REIC Gene Medicine in US
December 22, 2008
- DSP to Centralize Chinese Business Activities in Suzhou
December 22, 2008
- ICH GL for Exploratory Clinical Studies to Be Completed in June 2009
December 22, 2008
- Market in Emerging Countries to Grow to about US$300 Bil. in 2017
December 22, 2008
- R&D NEWS IN BRIEF
December 22, 2008
- Chugai, Chiome Sign Agreement on Monoclonal Antibody Production
December 15, 2008
- SELF-MEDICATION NEWS IN BRIEF
December 15, 2008
- BUSINESS NEWS IN BRIEF
December 15, 2008
- SURVEY／Diabetes Is Most Commonly Examined
December 15, 2008
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…